融入全球价值链扩大了发展中国家的工资差距吗？

研究目标：作为发展中国家的中国深入参与全球价值链分工是否会扩大国内工资差距。研究方法：基于WIOD数据库及WWZ方法,测算了1995~2011年中国主要13个制造业与12个服务业垂直专业化指数,并在三要素中间投入理论模型的基础上,实证分析了嵌入全球价值链程度对工资收入差距的影响。研究发现：与现有研究结果不同的是,本文发现随着制造业和服务业参与国际垂直专业化分工程度提高,进一步缩小了中国熟练和非熟练劳动力的工资差距,且服务业比制造业更加显著,但2003年前后出现分化。研究创新：本文采用新的VSS指数测算方法并新增服务业的分析视角。研究价值：分析融入GVC程度对中国制造业与服务业工资差距影响的差异及形成原因,并提出针对性建议。     

绥化市餐饮业经营分析与对策研究

绥化市作为东北地区的一个典型代表,在饮食习惯、餐饮业经营所需考虑的时间距离、空间距离、客源市场、经济发展以及城市交通等方面存在着诸多的特征,对这些特征的不正确掌握和消化使诸多的餐饮企业的经营举步维艰。笔者在对绥化市餐饮业经营环境进行充分分析的前提下,对绥化市餐坎企业的经营管理对策进行了研究。     

对构建创新型高等学校体育课程体系的研究

用问卷调查法、文献资料法和现代教育思想等基本方法解析高等学校学生针对目前体育课程设置的意见和学生学习兴趣、动机、取向。以终身体育和健康教育为出发点,对创新型高等学校教育教学模式、教学内容、课程特点及评价方法进行了综合分析和研究。指出了其个性化、终身化和健康化的思想对体育课程改革的意义。     

商业银行管理层股票期权激励:特征及其影响因素——基于美国银行业的实证研究

本文以1996～2005年间美国43家代表性商业银行和98家制造业企业为样本,实证分析了商业银行管理层股票期权补偿激励的特征和影响因素。结果表明:商业银行管理层股票期权补偿占总报酬补偿比例的变化呈现出先升后降的倒U型趋势,商业银行管理层股票期权补偿占总报酬补偿的比例显著地低于制造业的这一比例;管理层股票期权补偿与商业银行成长机会、外部董事比例存在着显著的正相关关系,而与杠杆比率呈显著负相关;资产规模、管理层股票补偿对股票期权补偿水平的影响为负,但不显著;行业管制与管理层股票期权补偿费用的会计处理方法对银行业股票期权补偿有显著的影响。     

关注预决算偏离度

对于不少人来说,"预决算偏离度"可能还是一个相对新鲜的概念。在既有的各类辞典和相关文献中,暂时还找不到准确的阐释。但是,至少从字面意义上可以获知,它指的是,在经立法机关审查批准的政府预算收支同作为其实际执行结果的政府     

Claims frequency modeling using telematics car driving data

We investigate the predictive power of covariates extracted from telematics car driving data using the speed-acceleration heatmaps of Gao, G. & Wüthrich, M. V. [(2017). Feature extraction from telematics car driving heatmaps. SSRN ID: 3070069]. These telematics covariates include K-means classification, principal components, and bottleneck activations from a bottleneck neural network. In the conducted case study it turns out that the first principal component and the bottleneck activations give a better out-of-sample prediction for claims frequencies than other traditional pricing factors such as driver's age. Based on these numerical examples we recommend the use of these telematics covariates for car insurance pricing.     

中央企业国际竞争力的实证研究——基于“十二五”时期国企改革的效果评价

“十二五”是我国经济社会发展的关键时期。随着我国对外开放程度进一步提高,国有企业“走出去”进程加快,国有企业以及作为“精锐部队”的中央企业与国际社会的互动增加,对全球市场的影响力已不可同日而语。深化国企改革,既是中国国有企业自身的战略需要,更是国家发展大战略的客观要求。本文基于中央企业在2011～2015年间的财务数据,构建了中央企业国际竞争力的四维评价体系,并用主成分分析法对我国33家中央企业进行实证分析,在此基础上探析“十二五”期间国企改革的进展和成效。     

国外品牌犯错研究述评与展望

以往的品牌犯错事件主要以产品伤害危机为主,近年来在社会规范和道德层面上也逐渐地有所体现,给企业和利益相关者带来了更广泛的影响,而现有品牌犯错的述评仍主要停留在品牌功能层面上（以产品伤害危机为主）,缺少系统全面的分析。本文在梳理国外文献基础上,围绕品牌犯错的含义、分类、相关变量及影响结果、应对策略等主题进行述评,探讨该领域的未来研究方向,以期为我国的品牌犯错理论研究和实践操作提供参考借鉴。     

Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada

Background and objective Venous thromboembolism (VTE) is associated with long-term clinical and economic burden. Clinical guidelines generally recommend at least 3 months of anticoagulation, but, in clinical practice, concerns over bleeding risk often limit extended treatment. Apixaban was studied for extended VTE treatment in the AMPLIFY-EXT trial, demonstrating superiority to placebo in VTE reduction without increasing risk of major bleeding. This study assessed the long-term clinical and economic benefits of extending treatment with apixaban when clinical equipoise exists compared to standard of care with enoxaparin/warfarin and other novel oral anti-coagulants (NOACs) for the treatment and prevention of recurrent VTE in Canada.

Methods A Markov model was developed to follow patients with VTE over their lifetimes. Efficacy and safety for apixaban and enoxaparin/warfarin were based on AMPLIFY and AMPLIFY-EXT, while relative efficacy to other NOACs was synthesized by network meta-analysis (NMA). Dosages for NOACs and enoxaparin/warfarin were based on their respective trials and were given up to 18 months and up to 6 months, followed by no treatment, respectively. Patient quality adjusted life years (QALYs) were based on published studies, and costs for resource utilization were from a Ministry of Health perspective, expressed as 2014 CAD ($).

Results Extended treatment with apixaban compared to enoxaparin/warfarin resulted in fewer recurrent VTEs, VTE-related deaths, and bleeding events, but at slightly increased cost. The incremental cost-effectiveness ratio was $4828 per QALY gained. Compared to other NOACs, apixaban had the fewest bleeding events, similar recurrent VTE events, and the lowest overall cost, which was driven by the strong bleeding profile. In scenario analyses of acute and lifetime treatments, apixaban was cost-effective against all strategies.

Conclusions Extended treatment with apixaban can offer substantial clinical benefits and is a cost-effective alternative to enoxaparin/warfarin and other NOACs.